Buy Persantine (Dipyridamole 25mg / 100mg) Online - Original Boehringer Brand German Remedies Antiplatelet

The main modern uses of Persantine

• 🧠 Secondary stroke prevention combined with aspirin - the ESPS-2 and ESPRIT trials established this indication; standard modified-release formulation is Aggrenox (in US) or Asasantin Retard (in Europe)
• ❤️ Adjunct to warfarin after mechanical heart valve replacement - reduces thromboembolism in specific higher-risk mechanical valve situations
• 📸 Pharmacologic myocardial perfusion stress imaging - IV dipyridamole vasodilates coronary vessels for stress test in clients unable to exercise
• 🧬 Occasional use in various vascular conditions - historical uses in peripheral vascular disease largely superseded

Secondary stroke prevention

The largest current indication. After an ischaemic stroke or transient ischaemic attack of non-cardioembolic origin, dipyridamole plus aspirin reduces the risk of recurrent stroke. The ESPS-2 trial and ESPRIT trial established this combination as more effective than aspirin alone. The PRoFESS trial showed similar efficacy versus clopidogrel monotherapy. Guidelines position dipyridamole plus aspirin, clopidogrel monotherapy, and aspirin monotherapy as acceptable options - the choice depends on tolerance, cost, and clinical factors. Section 3 covers this indication.

Mechanical heart valve thromboembolism prevention

In some clients with mechanical heart valves on warfarin, adding dipyridamole (or aspirin) further reduces thromboembolism risk - at the cost of additional bleeding risk. Modern practice varies; some centres use warfarin alone, others add low-dose aspirin, others use dipyridamole. Individualised on valve type, position, and thromboembolic risk factors. Section 4 covers this.

Pharmacologic cardiac stress testing

For clients unable to exercise adequately, IV dipyridamole (or its close alternative regadenoson) can pharmacologically stress the coronary circulation for myocardial perfusion imaging. Dipyridamole vasodilates normal coronary vessels; diseased vessels cannot dilate as much, revealing perfusion defects. Given in a supervised setting with cardiac monitoring. Section 5 covers this in depth.

Historical uses now uncommon

• Stable angina - was the original indication in 1961; not effective long-term for angina outcomes; supplanted by beta-blockers, calcium channel blockers, nitrates, and revascularisation
• Peripheral arterial disease - clopidogrel, aspirin, and cilostazol have taken over
• Deep vein thrombosis prophylaxis - anticoagulants preferred
• Retinal artery disease - specialist use only

Off-label and emerging uses

• Some interventional cardiology settings - post-stenting protocols in specific contexts
• Nephrology - occasional use in immune complex renal disease (immunomodulatory effects)
• Antiviral properties - dipyridamole has been investigated for various viral illnesses including COVID-19; not standard therapy
• Sickle cell disease - investigated for potential red cell effects; not standard

Guideline positioning summary

Secondary stroke prevention guidelines (AHA/ASA, ESO, NICE) list dipyridamole plus aspirin as one of the recommended first-line antiplatelet regimens for non-cardioembolic ischaemic stroke, alongside clopidogrel monotherapy and aspirin monotherapy. Choice depends on individual factors. In practice, the extra headache burden and twice-daily dosing sometimes tip the balance toward once-daily clopidogrel in the modern era. Pharmacologic stress testing remains an established and important indication for IV dipyridamole worldwide.

The stroke recurrence problem

• After a first ischaemic stroke or TIA, the risk of a recurrent stroke is high
• Roughly 10 percent within the first year
• Roughly 30 percent within 5 years without treatment
• Antiplatelet therapy reduces this risk by roughly 20-25 percent
• Blood pressure control, statins, lifestyle modification, and treating causal conditions (AF, carotid disease) all contribute

Dipyridamole plus aspirin evidence

Three major trials shaped the modern position:

• ESPS-2 (Diener et al. J Neurol Sci 1996) - 6,602 clients with prior stroke or TIA; four arms (placebo, aspirin alone, dipyridamole alone, both); combination reduced recurrent stroke by 37 percent versus placebo, more than either agent alone
• ESPRIT (Halkes et al. Lancet 2006) - 2,739 clients; combination reduced recurrent stroke, MI, or vascular death versus aspirin alone by 20 percent
• PRoFESS (Sacco et al. NEJM 2008) - 20,332 clients; dipyridamole plus aspirin versus clopidogrel monotherapy showed similar recurrent stroke rates; dipyridamole arm had more headaches and higher discontinuation rate

Modern antiplatelet options for secondary stroke prevention

Which client benefits most from dipyridamole plus aspirin

• Non-cardioembolic ischaemic stroke or TIA
• Client tolerating aspirin
• Able to accept twice-daily dosing
• Willing to tolerate initial headache burden
• Not cardioembolic (AF requires anticoagulation, not antiplatelet)
• Not severe cardiac disease (relative contraindication - see Section 32)
• Not intolerant of aspirin

Not for cardioembolic stroke

Strokes caused by cardiac emboli (mostly from atrial fibrillation, but also from mechanical valves, left ventricular thrombus, etc.) need anticoagulation, not antiplatelet therapy. Dipyridamole plus aspirin is inferior to anticoagulation for AF stroke prevention. Correctly categorising the stroke mechanism drives the correct therapy - and antiplatelets are for atherothrombotic and small-vessel disease, not cardioembolic.

Comprehensive secondary prevention alongside antiplatelet

• Blood pressure control (target under 130/80 in many)
• Statin therapy (LDL target under 70 mg/dL or 1.8 mmol/L in high risk)
• Smoking cessation
• Diabetes management
• Weight management and physical activity
• Screening for AF where relevant
• Carotid artery evaluation and intervention if severe stenosis
• Mediterranean-style diet

Why add antiplatelet to warfarin in mechanical valves

• Warfarin alone leaves residual thromboembolism risk (roughly 1-2 percent per year)
• Historical studies showed dipyridamole plus warfarin reduced embolism compared with warfarin alone
• More modern studies show low-dose aspirin (75-100 mg) also reduces thromboembolism
• Trade-off: additive bleeding risk (major bleeding roughly doubles)
• Guidelines recommend antiplatelet addition in specific higher-risk mechanical valve situations

Who should get antiplatelet plus warfarin

• Older-generation mechanical valve (caged-ball, tilting-disc)
• Mechanical mitral valve (higher thrombogenic risk than aortic)
• Multiple mechanical valves
• Prior thromboembolism despite therapeutic INR
• Concurrent AF
• Left atrial enlargement
• Left ventricular dysfunction
• Hypercoagulable state
• Coronary artery disease (aspirin serves dual purpose)

Modern guideline positioning

Both ACC/AHA and ESC/EACTS Valvular Heart Disease Guidelines recommend adding low-dose aspirin (75-100 mg) to warfarin in mechanical valve clients with additional risk factors. Dipyridamole is an alternative in some jurisdictions. In practice aspirin has largely displaced dipyridamole in this indication because of once-daily dosing, lower cost, and dual role covering coronary artery disease.

Increased bleeding risk

Adding any antiplatelet to warfarin roughly doubles the risk of major bleeding. Client selection matters. Clients with high HAS-BLED score, prior bleeding, uncontrolled hypertension, or advanced age may be net worse off with combination therapy. The decision balances the residual thromboembolism risk on warfarin alone against the incremental bleeding risk of adding antiplatelet.

Dipyridamole dose in this indication

• Traditional dose 75-100 mg three or four times daily (immediate-release)
• Or 200 mg twice daily (extended-release)
• Combined with warfarin at usual mechanical valve INR target
• Some centres use dipyridamole alone in place of aspirin; others use both
• Increasingly, aspirin plus warfarin is preferred over dipyridamole plus warfarin

DOAC contraindication for mechanical valves

DOACs are absolutely contraindicated in mechanical heart valves - the RE-ALIGN trial with dabigatran showed worse outcomes. Anticoagulation must be with warfarin. Antiplatelet addition (dipyridamole or aspirin) can be considered separately based on individual risk profile.

Why exercise stress alternative is sometimes needed

• Unable to exercise (arthritis, deconditioning, orthopaedic issues)
• Cannot reach target heart rate (beta-blocker use)
• Cannot interpret exercise ECG (left bundle branch block, paced rhythm, digoxin effect)
• Pre-operative risk stratification in clients unable to exercise
• Some specific coronary anatomy requiring pharmacologic assessment

How pharmacologic stress works

Dipyridamole (or adenosine, or regadenoson) causes maximal coronary vasodilation - roughly 4-fold increase in coronary flow in normal vessels. Diseased coronary arteries (with fixed stenosis) cannot dilate proportionately. The result is heterogeneous flow - normal vessels get more flow, diseased vessels less. Nuclear tracer (thallium-201 or technetium-99m sestamibi) distribution reveals this heterogeneity as perfusion defects. Areas supplied by diseased vessels appear as photon-deficient regions on imaging.

The dipyridamole stress protocol

1. Client pre-screening (avoid contraindications - severe asthma, recent MI, unstable angina)
2. 24-hour caffeine avoidance (methylxanthines block adenosine receptors and blunt the test)
3. Hold theophylline or other methylxanthines 24-48 hours prior
4. IV access, cardiac monitoring, resuscitation available
5. Dipyridamole 0.56 mg/kg infused over 4 minutes
6. Radiotracer injected 3-4 minutes after infusion completes
7. Continued monitoring for symptoms
8. Aminophylline available for reversal if severe symptoms (100-125 mg IV)
9. SPECT or PET imaging follows

Contraindications to dipyridamole stress test

• 🔴 Acute MI within 48 hours
• 🔴 Unstable angina
• 🔴 Severe uncontrolled hypertension
• 🔴 Severe symptomatic asthma or bronchospasm
• 🔴 Severe COPD with active wheezing
• 🔴 Systolic BP under 90 mmHg
• 🔴 High-grade AV block without pacemaker
• 🔴 Recent caffeine intake (blunts test)
• 🔴 Known dipyridamole hypersensitivity

Common side effects during test

• Flushing
• Chest discomfort (not always ischaemic - dipyridamole itself can cause)
• Headache
• Dizziness
• Nausea
• Hypotension
• Occasional bronchospasm
• Most effects settle rapidly; aminophylline reverses if severe

Alternatives to dipyridamole for pharmacologic stress

• Adenosine - shorter half-life; more transient effect; requires continuous infusion
• Regadenoson - selective A2A agonist; single injection; less bronchospasm risk than dipyridamole or adenosine; increasingly preferred in modern practice
• Dobutamine - increases heart rate and contractility; alternative when vasodilator contraindicated (severe asthma); more time-consuming

The rationale for combination

• Complementary mechanisms - aspirin blocks thromboxane A2 pathway; dipyridamole works through cAMP/adenosine pathway; targets different aspects of platelet activation
• Additive effect - combination reduces stroke recurrence more than either alone (ESPS-2)
• Modest aspirin dose (25 mg twice daily) - lower total daily aspirin (50 mg) than typical monotherapy (75-100 mg); may reduce GI bleeding compared to 100 mg
• Extended-release dipyridamole - steadier serum levels, twice-daily dosing acceptable
• Single capsule - simplifies adherence

Aggrenox / Asasantin Retard composition

• 200 mg extended-release dipyridamole per capsule
• 25 mg immediate-release aspirin per capsule
• Twice daily (morning and evening)
• Total daily dose: 400 mg dipyridamole + 50 mg aspirin
• Capsule contains both components in fixed ratio
• Should be swallowed whole - do not open capsule

Alternative regimens if combination unavailable

• Aspirin 25-50 mg twice daily plus dipyridamole IR 75-100 mg three or four times daily
• Aspirin 75-100 mg once daily plus dipyridamole ER 200 mg twice daily (separate tablets)
• The combination capsule is preferred where available for adherence reasons
• Dipyridamole IR at 75-100 mg three or four times daily produces equivalent antiplatelet effect but requires more frequent dosing

Practical daily routine

• One capsule morning (with breakfast)
• One capsule evening (with dinner)
• Take with water
• With or without food (food slightly reduces GI upset)
• Do not open, crush, or chew the capsule
• If a capsule is missed, take when remembered unless close to next dose; never double up

Headache burden in combination

Headache is the dominant early side effect - roughly 30-40 percent of clients experience it in the first weeks. Two approaches help:

• Gradual titration - some centres start with once-daily capsule for 1-2 weeks, then twice daily (though the fixed-dose combination is not designed for once-daily use, and evidence supports twice-daily from the start)
• Paracetamol for headache - first-line; effective in most
• Headache typically improves over 2-4 weeks of continued therapy
• Discontinuation for headache in the PRoFESS trial was substantially higher for dipyridamole plus aspirin than for clopidogrel alone

Not the same as taking aspirin plus dipyridamole separately

The extended-release dipyridamole in Aggrenox provides steadier drug levels than immediate-release dipyridamole taken multiple times daily. Do not substitute immediate-release dipyridamole 200 mg twice daily for the extended-release formulation - peaks and troughs are different. Both formulations work but the fixed-dose combination gives the specific pharmacokinetics tested in the pivotal trials.

Mechanism 1 - phosphodiesterase inhibition

1. Platelets contain phosphodiesterase enzymes that break down cAMP and cGMP
2. cAMP normally suppresses platelet activation - low cAMP allows activation
3. Dipyridamole inhibits platelet phosphodiesterase
4. cAMP levels rise
5. Platelet activation, aggregation, and granule release suppressed
6. Antithrombotic effect at sites of vascular injury

Mechanism 2 - adenosine reuptake inhibition

1. Adenosine is a naturally released signalling molecule
2. Normally rapidly taken up into cells by equilibrative nucleoside transporter 1 (ENT1)
3. Dipyridamole blocks ENT1
4. Extracellular adenosine levels rise
5. Adenosine binds A2A receptors on platelets - activates adenylyl cyclase - raises cAMP - suppresses activation
6. Adenosine also binds A2A receptors on vascular smooth muscle - relaxes vessels - vasodilation
7. Adenosine also acts on cerebral vessels (headache) and coronary vessels (basis of stress test)

Why dipyridamole complements aspirin

Aspirin acetylates cyclooxygenase-1 (COX-1) in platelets, blocking thromboxane A2 synthesis. This addresses one pathway of platelet activation. Dipyridamole raises cAMP through independent mechanisms, addressing a different pathway. The two drugs suppress different aspects of platelet activation - hence the additive effect demonstrated in ESPS-2.

The vascular effects

• Cerebral vasodilation - causes headache; also relevant in migraine considerations
• Coronary vasodilation - the basis of pharmacologic stress testing; also potential steal syndrome in coronary disease
• Systemic vasodilation - can cause hypotension particularly at high doses
• Bronchial adenosine effects - can trigger bronchospasm in asthma clients

Pharmacokinetics

• Oral bioavailability - variable (20-70 percent) due to first-pass metabolism
• Extended-release formulation - smoothes absorption curve
• Peak plasma level - 2-3 hours after IR dose; 6-8 hours after ER
• Half-life - biphasic; terminal 10-12 hours
• Highly protein bound - drug interactions possible via displacement
• Hepatic metabolism - glucuronide conjugation
• Excreted in bile - enterohepatic recirculation
• Not dialysable

Caffeine blocks the adenosine mechanism

Caffeine and other methylxanthines (theophylline, aminophylline) are adenosine receptor antagonists. They block the effects of raised extracellular adenosine at A2A receptors. This is why caffeine avoidance is essential before pharmacologic stress testing with dipyridamole - caffeine within 24 hours blunts the test and makes it uninterpretable. Aminophylline is used deliberately to reverse severe dipyridamole side effects during stress tests.

Standard dosing by indication

Timing rules for oral dipyridamole

• Twice-daily ER (Aggrenox) - morning and evening; 10-12 hours apart
• Three-times daily IR - roughly 8 hours apart, aligned to meals
• Four-times daily IR - every 6 hours
• With food - reduces GI upset; slight absorption benefit
• Consistent timing matters more than exact hour
• Do not open ER capsules - releases drug immediately, changes pharmacokinetics

The bedtime dose consideration

Some clients experience worse dizziness or hypotension in the morning if the last dose is taken very late. Evening dose is typically taken with dinner (6-7 PM) rather than at bedtime. This is different from many other cardiovascular medications - the vasodilation from dipyridamole can accumulate through the night with orthostatic issues on rising.

Practical daily schedule for Aggrenox

• Morning capsule with breakfast (7-8 AM)
• Evening capsule with dinner (6-7 PM)
• Water, not with grapefruit juice
• Space at least 8-10 hours apart
• Consistency helps sustained antiplatelet effect

Dose adjustment for renal or hepatic function

• Dipyridamole is hepatically metabolised
• No specific dose reduction for renal impairment
• Caution in severe hepatic impairment
• Aspirin component - avoid at eGFR under 30 particularly if bleeding risk factors present
• Elderly - standard dose usually, but consider slower titration if headache limiting

If headache is severe in first weeks

• Take with food (some benefit)
• Paracetamol first-line for headache relief
• Consider brief once-daily dosing for 1-2 weeks then twice daily (though evidence base for this titration approach is limited)
• Reassure - headache usually improves over 2-4 weeks
• Persistent severe headache may need switch to alternative antiplatelet

The typical initiation experience

• Headache often begins within the first days of starting
• Peak intensity in the first 1-2 weeks
• Gradual improvement over 2-4 weeks
• Roughly 30-40 percent of clients experience meaningful headache
• Roughly 10 percent discontinue therapy for headache
• Once past the initial period, most clients continue for years without issue

The gradual titration option

Some prescribers use a titration approach for the first 1-2 weeks to reduce headache burden - one capsule at night for a week, then progressing to full twice-daily. This is not the FDA-approved regimen and evidence base is limited, but many practitioners find it improves initial tolerability. Discuss with your treating team whether this approach fits your situation. If clinical urgency requires full antiplatelet effect from day one (very recent high-risk stroke), full-dose start with headache management is preferred.

Headache management strategies

1. Paracetamol 500-1000 mg at first sign of headache; effective for most; safe with dipyridamole
2. Take with food - slight absorption benefit and reduced GI upset
3. Hydration - adequate fluid intake helps
4. Cool compress to forehead
5. Rest in dark room during peak headache
6. Reduce caffeine - both because dipyridamole disrupts adenosine effects (caffeine may paradoxically not help these headaches) and because caffeine withdrawal itself causes headache
7. Avoid NSAIDs combined with dipyridamole plus aspirin (bleeding risk) unless specifically directed
8. Reassurance that headache usually improves

Symptoms to monitor early

• Headache - character, severity, response to paracetamol
• Dizziness on standing
• Nausea or GI upset
• Any unusual bleeding (from combination with aspirin)
• Flushing
• Chest discomfort (uncommon but worth noting)
• Wheeze or breathing difficulty in known asthmatics

Symptoms that need urgent review

• 🔴 Sudden severe headache different from usual dipyridamole headache
• 🔴 Focal neurological symptoms (arm/leg weakness, speech difficulty, vision changes) - possible new stroke or TIA
• 🔴 New chest pain
• 🔴 Severe dizziness or syncope
• 🔴 Wheeze or shortness of breath
• 🔴 Any significant bleeding
• 🔴 Rash

When to consider switching

• Severe headache not responding to paracetamol after 4 weeks
• Significant impact on quality of life or work
• Bleeding complications
• GI intolerance from aspirin component
• Clopidogrel monotherapy is the most common alternative
• Aspirin monotherapy also acceptable
• Discussion with neurologist or GP

Factors affecting individual response

• Bioavailability variability - substantial (20-70 percent oral); explains individual level differences
• Age - modest effect on pharmacokinetics
• Body weight - larger clients may have lower effective concentration but standard fixed dosing works for most
• Concurrent medications - some interactions raise or lower level (Section 20)
• Hepatic function - metabolism affected by cirrhosis; caution
• Baseline platelet function - responsiveness varies but not routinely measured

Standard adjustments

No routine level or platelet function monitoring

Unlike warfarin (INR) or digoxin (serum level), dipyridamole is not routinely monitored by blood test. Platelet function tests have been used in research but do not routinely guide dose in clinical practice. Effectiveness is judged clinically by absence of recurrent stroke events. Side effects are judged by client symptoms.

Long-term consistency

• Once established, the regimen is not routinely changed
• Same dose for years
• Periodic review of overall vascular risk (statin, BP, lifestyle)
• Reassessment if new bleeding, new stroke event, or planned procedure
• Consider deprescribing in advanced age or advanced comorbidity if bleeding risk exceeds benefit

The clopidogrel switch decision

If dipyridamole plus aspirin is not tolerated, clopidogrel monotherapy is the most common switch. The PRoFESS trial showed similar efficacy between the two options; the choice often comes down to tolerability. Once-daily clopidogrel is simpler to take. Discuss with your neurologist if considering the switch.

Practical daily routine

• Twice daily - morning and evening for Aggrenox / ER dipyridamole
• Three or four times daily for IR dipyridamole regimens
• Same times each day - consistency helps steady antiplatelet effect
• With water - a full glass
• With food - preferred; reduces GI upset and slightly improves absorption
• Do not open ER capsules - releases drug immediately, changes pharmacokinetics
• Do not chew or crush IR tablets unless specifically instructed
• Refill 2 weeks before running out

Anchor doses to daily habits

• Morning capsule with breakfast
• Evening capsule with dinner
• Weekly pillbox with morning/evening compartments
• Phone alarms at each dose time
• Family or partner cross-check for those with cognitive concerns

Capsule opening prohibited

Aggrenox and Asasantin Retard capsules contain extended-release dipyridamole beads plus immediate-release aspirin. Opening the capsule and taking the contents defeats the ER design - dipyridamole is absorbed all at once, causing peak concentrations, worse headache, and shorter duration of effect. If the client cannot swallow capsules, alternative regimens with IR dipyridamole tablets should be arranged - not opening of ER capsules.

Common medication safety issues

• 🔴 Never double up on missed dose
• 🔴 Avoid additional aspirin from OTC products (Aggrenox already contains aspirin)
• 🔴 Avoid NSAIDs that would add to bleeding risk
• 🔴 Any new medication - check for interaction
• 🔴 Report any planned procedure to allow anticoagulation planning
• 🔴 Never take an extra dose for a bad headache - dose does not cause headache in dose-response manner
• 🔴 Wear medical alert bracelet noting antiplatelet therapy

Storage and handling

• Room temperature under 25 C in original packaging
• Protect from light and moisture
• Not in bathroom
• Not in hot car
• Out of reach of children
• Do not use past expiry
• Return unused capsules to pharmacy

Bleeding awareness

• Aggrenox contains aspirin - antiplatelet bleeding risk
• Watch for nosebleeds beyond usual, gum bleeding, easy bruising
• Any dark stools, blood in urine, coffee-ground vomit - urgent review
• Head injury - low threshold for medical review even without symptoms
• Menstrual heavy bleeding - discuss with team

Caffeine and dipyridamole - two different rules

• Daily oral dipyridamole (Aggrenox) - moderate caffeine intake is compatible; consistent daily habit matters more than absolute amount; caffeine may modestly reduce some effects but not clinically important for stroke prevention
• Pharmacologic stress test with IV dipyridamole - complete caffeine avoidance for 24 hours prior is essential; caffeine blocks adenosine A2A receptors and blunts the test

Complete caffeine avoidance 24 hours before stress test

• 🔴 No coffee (regular or decaf - even decaf has some caffeine)
• 🔴 No tea (regular or green)
• 🔴 No chocolate
• 🔴 No cola or caffeinated soft drinks
• 🔴 No energy drinks
• 🔴 No caffeine-containing medications (Anadin Extra, Solpadeine, Excedrin, Panadol Extra)
• 🔴 Hold theophylline or aminophylline 24-48 hours before
• 🔴 Section 31 covers stress test preparation in detail

Daily oral dipyridamole and diet

• No major dietary interactions with daily oral dipyridamole
• Take with food to reduce GI upset
• Normal caffeine intake acceptable if consistent
• Alcohol - modest intake acceptable (Section 13)
• Grapefruit juice - minimal interaction; occasional intake fine
• Standard heart-healthy diet supports overall stroke prevention

Stroke prevention diet foundation

• Mediterranean-style diet - fish, olive oil, vegetables, whole grains, nuts, legumes
• Reduced red meat and processed food
• Adequate hydration - 1.5-2 litres daily
• Modest salt restriction (under 5 g daily) for blood pressure
• Weight management
• Alcohol modest at most
• Regular physical activity as tolerated

Herbal supplements caution

• 🟡 Ginkgo biloba - antiplatelet effect; may add to bleeding risk on Aggrenox
• 🟡 Garlic (high-dose supplements) - antiplatelet effect
• 🟡 Ginseng - variable platelet effects
• 🟡 Ginger (high-dose) - antiplatelet effect
• 🟡 Fish oil (over 3 g daily) - bleeding risk additive
• 🟡 Vitamin E (high doses) - antiplatelet effect
• Culinary use of any of these is fine; supplement doses may matter

Why alcohol matters on antiplatelet therapy

• GI bleeding risk - alcohol damages gastric mucosa; combined with aspirin in Aggrenox this increases upper GI bleeding risk
• Direct antiplatelet effect - alcohol has some platelet-inhibiting activity; adds modestly to combined antiplatelet effect
• Blood pressure effect - alcohol raises BP; harms secondary stroke prevention
• Atrial fibrillation trigger - can trigger new AF (holiday heart syndrome)
• Fall risk - dizziness and postural issues on Aggrenox already; alcohol adds
• Overall stroke risk - heavy intake independently raises stroke risk

Practical guidance

Binge drinking is particularly dangerous

Binge drinking (4 or more drinks in a session) triggers acute BP rises, can cause AF, dramatically increases fall risk with antiplatelet-associated bleeding, and can trigger stroke directly. Modest consistent intake spread across the week with alcohol-free days is much safer than periodic binges.

Practical rules

• Alcohol-free days between drinking days
• Never drink to excess
• With food, never on empty stomach
• Hydration alongside
• Be honest with treating team about intake
• Support systems if alcohol use is an issue - depression and alcohol misuse both common after stroke

Side effect frequency for Aggrenox (from PRoFESS)

Warning signs - contact treating team urgently

• 🔴 Sudden severe headache different from usual - possible stroke or intracranial haemorrhage
• 🔴 Focal neurological symptoms (arm/leg weakness, speech difficulty, vision loss)
• 🔴 New chest pain - possible ischaemia (steal syndrome)
• 🔴 Uncontrolled bleeding
• 🔴 Vomiting blood or black stools
• 🔴 Severe wheeze or shortness of breath
• 🔴 Severe dizziness or syncope
• 🔴 Head injury - low threshold for medical review even without symptoms (on aspirin)

Perspective on side effects

The PRoFESS trial showed that clients discontinued Aggrenox at higher rates than clopidogrel, mostly because of headache. But for those who tolerated it, stroke prevention benefit was similar. The trade-off is real - headache is the price of the additional antiplatelet mechanism. Understanding this in advance improves the chance of successfully completing the initiation period and reaching sustained benefit.

Why dipyridamole causes headache

• Dipyridamole raises extracellular adenosine
• Adenosine acts on cerebral vessels causing vasodilation
• Cerebral vasodilation stretches meningeal blood vessel walls
• Meningeal nerve fibres detect stretch and generate pain
• Similar mechanism to migraine
• Vascular headache pattern - throbbing, worse with movement or straining

The typical headache pattern

• Onset - within first few doses (day 1-3)
• Character - throbbing, sometimes bilateral, temporal or frontal
• Intensity - mild to moderate; occasionally severe
• Duration - hours; often follows dose timing
• Peak burden - first 1-2 weeks
• Improvement - gradual over 2-4 weeks
• Long-term - most clients past 4 weeks have minimal headache
• Migraine history can predispose to worse initial headache

Management strategies

1. Paracetamol 500-1000 mg at onset or prophylactically - safe with Aggrenox; effective for most
2. Take with food to reduce absorption peaks
3. Adequate hydration - dehydration worsens
4. Cool compress to forehead
5. Rest in dark room during peak
6. Gradual titration approach - one capsule daily for 1-2 weeks, then twice daily (informal; not FDA approved regimen)
7. Reassure client that improvement typically comes with persistence
8. Consider switching if severe and persistent beyond 4 weeks despite management

Avoid these treatments for dipyridamole headache

• 🔴 NSAIDs (ibuprofen, naproxen) - additive bleeding risk with aspirin in Aggrenox
• 🔴 Triptans (sumatriptan) - vasoconstrictor; theoretical concern with antiplatelet stroke prevention client; discuss with team
• 🔴 Ergotamine - vasoconstrictor; contraindicated in cerebrovascular disease
• 🔴 Aspirin extra - already contained in Aggrenox; more aspirin does not help headache
• 🔴 Codeine or opioids - constipation, dependence, not first-line

Distinguishing dipyridamole headache from concerning causes

• Dipyridamole headache - onset with drug start, follows dose timing, throbbing, responds to paracetamol, improves over weeks
• Stroke or TIA - sudden, focal neurological deficit, may include headache but not the only feature
• Intracranial haemorrhage - sudden thunderclap severe headache, may have neurological deficit
• Cerebral venous sinus thrombosis - progressive headache with focal signs or seizures
• Migraine - unilateral, with aura, photophobia, phonophobia, nausea
• Sudden severe unfamiliar headache - always warrants urgent review, particularly on antiplatelet

Dizziness

• Often accompanies headache
• Vasodilation with orthostatic component
• Rise slowly from lying or sitting
• Consider timing of dose relative to activity
• Improves over weeks similar to headache
• Distinguish from neurological cause (new stroke)

Bleeding risk with Aggrenox

• Major bleeding - roughly 1-2 percent per year (similar to aspirin monotherapy)
• GI bleeding - roughly 3-5 percent lifetime; the most common serious bleeding
• Intracranial haemorrhage - roughly 0.5-1 percent per year
• Minor bleeding (bruising, epistaxis, gum bleeding) - common
• Comparable to aspirin monotherapy; not substantially higher
• Higher than antiplatelet-free but the stroke reduction typically outweighs

Bleeding risk factors

• Older age
• Prior GI bleeding or peptic ulcer disease
• Uncontrolled hypertension
• Concurrent anticoagulation
• Concurrent NSAIDs
• Concurrent corticosteroids
• Concurrent SSRIs
• Alcohol excess
• Liver disease
• Chronic kidney disease
• Helicobacter pylori infection
• Falls

Reducing bleeding risk practically

• 🟢 Consider PPI (omeprazole, esomeprazole, lansoprazole) for older clients or those with GI risk factors - reduces GI bleeding by roughly half
• 🟢 Blood pressure control (under 140/90 or as advised)
• 🟢 Test and treat Helicobacter pylori if not previously done
• 🟢 Avoid NSAIDs, corticosteroids where possible
• 🟢 Modest alcohol at most
• 🟢 Fall prevention
• 🟢 Soft toothbrush; electric razor
• 🟢 Avoid contact sports
• 🟢 Report any bleeding early

Emergency signs

• 🔴 Vomiting blood or coffee-ground vomit
• 🔴 Black tarry stool (melena) or fresh blood per rectum
• 🔴 Blood in urine beyond a streak
• 🔴 Sudden severe headache different from dipyridamole pattern
• 🔴 Focal neurological symptoms - possible intracranial haemorrhage
• 🔴 Head injury even without immediate symptoms
• 🔴 Uncontrolled bleeding from any wound
• 🔴 Feeling faint or dizzy with pallor - possible internal bleeding

Bleeding management

• Minor bleeding - direct pressure; local measures; usually settles
• Nosebleeds - pinch soft nose 10 minutes; lean forward; ice pack
• Cuts - direct pressure longer than usual
• Major bleeding - emergency department; stop Aggrenox; platelet transfusion may be considered
• Intracranial haemorrhage - emergency neurosurgery consultation; platelet transfusion for critical cases
• Head injury - CT scan regardless of symptoms

Why dipyridamole lowers BP

• Raises extracellular adenosine
• Adenosine binds A2A receptors on vascular smooth muscle
• Vasodilation reduces systemic vascular resistance
• Modest effect at oral doses; larger effect with IV bolus (stress test)
• Orthostatic component in some clients

Who is at risk

• Older adults with baroreflex impairment
• Concurrent antihypertensive medications
• Concurrent alpha-blockers for BPH
• Volume depletion (diuretics, poor intake, illness)
• Autonomic failure (Parkinsons, MSA, diabetes)
• Recent MI or reduced cardiac output
• Aortic stenosis (fixed obstruction)

Practical management

• Rise slowly from lying to sitting to standing
• Adequate hydration
• Time morning dose after breakfast
• Review other BP medications for optimisation
• Home BP monitoring standing and sitting
• Compression stockings if severe postural symptoms
• Consider switch to alternative antiplatelet if symptomatic

Warning signs

• 🔴 Persistent dizziness on standing
• 🔴 Syncope
• 🔴 Falls attributable to dizziness
• 🔴 Consistent home BP under 90 systolic
• 🔴 Chest pain with dizziness (could suggest coronary ischaemia)

How steal syndrome works

1. Normal coronary vessels dilate maximally under dipyridamole (adenosine mechanism)
2. Vessels supplying ischaemic myocardium are already maximally dilated at baseline (endogenous adenosine from the ischaemia)
3. Ischaemic vessels cannot dilate further
4. Blood flow shifts to newly dilated normal vessels
5. Ischaemic areas receive less perfusion - the blood is "stolen" from them
6. Can worsen ischaemia in vulnerable coronary segments

Clinical implications

• Basis of the pharmacologic stress test - reveals ischaemic areas on imaging
• Rare cause of chest pain during test - happens in perhaps 5-10 percent of stress tests
• Reason for contraindication in recent MI or unstable angina - risk of precipitating further ischaemia
• Not clinically important with chronic oral therapy in stable clients - the slower pharmacokinetics avoid the peak vasodilator effect that IV bolus produces
• Theoretical concern in severe unstable CAD - most clinicians avoid or use with caution

Warning signs during stress test

• 🔴 New or worsening chest pain
• 🔴 ST depression on ECG
• 🔴 Dysrhythmia
• 🔴 Severe hypotension
• 🔴 Managed by aminophylline reversal and standard cardiac care

Chronic oral dipyridamole and CAD

In stable coronary artery disease, chronic oral dipyridamole at doses used for stroke prevention does not typically cause clinical steal syndrome. The pharmacokinetics do not produce the peak vasodilator effect of IV bolus. Nevertheless, clients with severe stable angina, recent MI, or unstable coronary disease should have specialist review before starting - the balance of stroke prevention versus theoretical coronary concern needs individual assessment.

Practical implications for oral therapy

• Avoid in unstable angina
• Avoid within 4-6 weeks of MI
• Caution in severe stable angina - discuss alternatives
• Consider clopidogrel monotherapy as alternative
• Report new anginal symptoms while on therapy
• Steal syndrome as clinical event is uncommon with oral therapy

Why adenosine causes bronchospasm in asthma

• Adenosine binds A2B receptors on bronchial mast cells
• Triggers release of histamine and other inflammatory mediators
• Bronchoconstriction in susceptible clients
• Also direct bronchial smooth muscle effects
• Effect is amplified in reactive airways
• Not usually a problem in non-asthmatic clients

Contraindications and cautions

• 🔴 Severe symptomatic asthma or bronchospasm - IV stress test contraindicated
• 🔴 Severe COPD with active wheezing - contraindicated for stress test
• 🔴 Prior bronchospasm during IV dipyridamole - do not rechallenge
• 🟡 Well-controlled asthma - relative contraindication; may consider regadenoson or dobutamine instead
• 🟡 COPD without active bronchospasm - relative caution
• 🟡 Oral therapy in stable asthma - usually safe but monitor initially

Warning signs during IV administration

• Chest tightness
• Wheeze
• Shortness of breath
• Cough
• Reduced oxygen saturation
• Managed by aminophylline reversal, bronchodilators, oxygen, standard bronchospasm care

Practical rules for asthma clients on oral therapy

• Well-controlled asthma is generally not a contraindication to Aggrenox
• Continue usual asthma inhalers as prescribed
• Report any wheeze, chest tightness, or new asthma exacerbation
• Consider alternative antiplatelet if any breathing concerns
• Clopidogrel does not have this specific bronchospasm concern

Aspirin component adds respiratory concerns

Aggrenox contains aspirin which can trigger aspirin-exacerbated respiratory disease (Samter's triad) in susceptible clients - asthma, nasal polyps, and aspirin sensitivity. Any client with known aspirin sensitivity should not take Aggrenox. Alternative regimens (clopidogrel alone) avoid both the aspirin and the dipyridamole concerns.

Adenosine-related interactions

• 🔴 Adenosine (IV, used for supraventricular tachycardia) - dipyridamole potentiates adenosine effects up to 4-fold; reduce adenosine dose by 75 percent if given to a client on dipyridamole
• 🔴 Methylxanthines (caffeine, theophylline, aminophylline, pentoxifylline) - block adenosine receptors; antagonise dipyridamole effect; caffeine avoidance for stress test
• 🔴 Regadenoson - other adenosine A2A agonist; not used together

Additive bleeding interactions

• 🟡 Warfarin - additive bleeding risk; combination sometimes used deliberately (mechanical valves) but with awareness
• 🟡 Direct oral anticoagulants (DOACs) - additive bleeding risk; combination usually avoided
• 🟡 Other antiplatelet agents (clopidogrel, prasugrel, ticagrelor, cilostazol) - additive antiplatelet effect; triple therapy generally avoided
• 🟡 NSAIDs - additive bleeding risk and GI mucosal damage; avoid where possible
• 🟡 SSRIs and SNRIs - modest additive bleeding risk via platelet serotonin depletion
• 🟡 Corticosteroids - additive GI bleeding risk with aspirin component

Aspirin component interactions (Aggrenox)

• All aspirin interactions apply
• Anticoagulants - bleeding risk
• Methotrexate - aspirin can raise MTX levels
• ACE inhibitors, ARBs - reduced hypotensive effect at higher aspirin doses; not usually significant at 25 mg twice daily
• Sulfonylureas - increased hypoglycaemia risk
• Uricosurics (probenecid) - reduced uric acid excretion
• Alcohol - increased GI mucosal damage

BP-affecting interactions

• 🟡 Antihypertensives generally - additive BP-lowering; monitor
• 🟡 PDE5 inhibitors (sildenafil, tadalafil) - additive vasodilator effect; caution
• 🟡 Alpha-blockers - orthostatic hypotension additive

Combinations that are usually fine

• 🟢 Paracetamol (preferred pain reliever)
• 🟢 Statins
• 🟢 ACE inhibitors, ARBs, beta-blockers, CCBs at usual doses
• 🟢 Metformin, SGLT2 inhibitors
• 🟢 Levothyroxine
• 🟢 PPIs (often specifically added to reduce GI bleeding risk)
• 🟢 Most antibiotics
• 🟢 Vaccines

Rules to work by

1. Tell every doctor, pharmacist, and dentist about Aggrenox/dipyridamole
2. Check every new prescription for interactions
3. Avoid over-the-counter NSAIDs unless specifically directed
4. Check cold and flu remedies for hidden aspirin or NSAIDs
5. Never take herbal antiplatelet supplements without checking
6. Wear medical alert bracelet noting antiplatelet therapy
7. Keep an updated medication list

Dipyridamole plus aspirin (Aggrenox)

• The evidence-based combination
• ESPS-2 and ESPRIT established benefit
• Bleeding rates similar to aspirin monotherapy
• Standard regimen 200 mg ER dipyridamole + 25 mg aspirin twice daily

Combinations to avoid

• 🔴 Aggrenox plus clopidogrel - triple antiplatelet; not routinely justified; bleeding risk high
• 🔴 Aggrenox plus prasugrel or ticagrelor - triple antiplatelet; specialist only
• 🔴 Dipyridamole plus aspirin plus warfarin - triple therapy; only in mechanical valve settings and time-limited
• 🔴 Aggrenox plus DOAC - additive bleeding; specialist only

Specific clinical scenarios

• Recent PCI in a client on Aggrenox - short-term dual antiplatelet often needed; specialist decides how to manage overlap
• New AF in a client on Aggrenox - switch to anticoagulation (warfarin or DOAC); antiplatelet not adequate for AF stroke prevention
• New coronary artery disease requiring dual antiplatelet - typically stop Aggrenox and use aspirin plus P2Y12 inhibitor
• Recurrent stroke despite Aggrenox - specialist review; may switch antiplatelet or add other measures

Dual antiplatelet after high-risk TIA or minor stroke

The CHANCE and POINT trials established that short-term (21-90 days) aspirin plus clopidogrel is superior to aspirin monotherapy for the first weeks after high-risk TIA or minor stroke. This is a specific limited-duration indication - not Aggrenox territory. After the acute period, transition to single antiplatelet (options include dipyridamole plus aspirin, clopidogrel alone, or aspirin alone) for chronic secondary prevention.

Switching between antiplatelet options

• Aggrenox to clopidogrel - straight switch; stop Aggrenox, start clopidogrel next day
• Aggrenox to aspirin monotherapy - straight switch; continue aspirin
• Clopidogrel to Aggrenox - straight switch
• Aspirin to Aggrenox - straight switch
• No cross-titration usually needed

Dipyridamole plus warfarin

• Mechanical heart valve - specific recommendation in higher-risk clients (Section 4)
• Additive bleeding risk - roughly doubles compared to warfarin alone
• Modern preference - aspirin instead of dipyridamole for this indication
• Where used - traditionally 75-100 mg three or four times daily added to warfarin at target INR 2.5-3.5
• Monitoring - standard warfarin INR plus attention to bleeding

Aggrenox plus warfarin - generally avoided

The combination of Aggrenox (which contains aspirin) plus warfarin is triple antithrombotic therapy - aspirin, dipyridamole, and warfarin. Bleeding risk is substantial. Modern practice generally avoids this combination. If both indications exist (mechanical valve requiring anticoagulation and stroke prevention need), the usual approach is warfarin plus low-dose aspirin, not Aggrenox plus warfarin.

Dipyridamole plus DOAC

• Not a standard combination
• Additive bleeding risk
• DOACs are for AF or VTE - antiplatelet not adequate for AF alone but sometimes combined for CAD
• Specific scenarios (AF plus recent PCI) may need combination briefly
• Individual specialist decision

The bleeding calculation

• Anticoagulant alone - baseline bleeding rate 1-2 percent per year for major bleeding
• Add aspirin - roughly doubles
• Add Aggrenox - similar to adding aspirin plus dipyridamole; substantial additive
• Add clopidogrel - triple therapy; substantial bleeding
• Client selection matters - HAS-BLED score guides risk assessment
• PPI cover reduces GI bleeding roughly by half

Modern practical decisions

• AF stroke prevention - anticoagulation (warfarin or DOAC); antiplatelet not adequate; do not combine unless specific coronary indication
• Mechanical valve - warfarin; consider adding low-dose aspirin (not Aggrenox) in higher-risk clients
• Stroke prevention (non-cardioembolic) - antiplatelet (Aggrenox, clopidogrel, or aspirin monotherapy)
• New AF in a client on Aggrenox - switch to anticoagulation; discontinue Aggrenox
• Recent PCI plus AF plus previous stroke - complex; specialist team decides on brief triple therapy versus double

The core rule

• Within a few hours of usual time: take the missed dose
• More than 4-6 hours late and next dose approaching: skip missed dose, take next dose at usual time
• Never double up
• One or two missed doses have minimal consequence
• Consistent adherence over months matters more than perfect timing

Longer gaps

• Missed a day: restart usual regimen next day
• Missed a week: restart; consider whether headache burden might restart (usually not after initial period)
• Stopped for weeks: discuss with treating team; may need brief re-titration for headache
• Silent discontinuation: raises stroke recurrence risk; discuss honest reasons for stopping with treating team

When missed doses become a pattern

• 🔴 Side effects making the drug unpleasant - discuss switch to alternative
• 🔴 Twice-daily schedule difficult - once-daily clopidogrel may fit better
• 🔴 Cognitive difficulty - family involvement, pillbox
• 🔴 Cost - discuss alternatives
• 🔴 Feeling well without it - discuss but do not silently stop

Practical adherence tools

• Weekly pillbox with morning/evening compartments
• Phone alarms twice daily
• Anchor to meals
• Adherence apps
• Refill 2 weeks before running out

Baseline before starting

• Full blood count
• Renal function
• Liver function
• Blood pressure
• Review of concurrent medications
• Assessment of contraindications (recent MI, unstable angina, severe asthma)
• Documentation of baseline neurological status

Follow-up schedule

Broader secondary stroke prevention monitoring

• Blood pressure - target under 130/80 in many; measure at least yearly
• Lipids and statin - LDL target under 70 mg/dL or 1.8 mmol/L high-risk
• Diabetes - HbA1c if diabetic
• Weight and lifestyle
• Screening for AF if not previously present (particularly cryptogenic stroke)
• Carotid imaging if not previously done
• Vaccination status

Symptoms to track

• Headache pattern (persistent or improved)
• Dizziness
• Bleeding (nosebleeds, bruising, GI, urinary)
• GI upset from aspirin component
• Chest pain (uncommon but concerning)
• Wheeze in asthmatic clients
• Any new neurological symptoms - possible recurrent stroke or TIA

What changes with age

• Higher stroke recurrence risk - benefits from prevention are larger absolute
• Higher bleeding risk - GI and intracranial haemorrhage rates rise with age
• Higher fall risk - dizziness on dipyridamole adds; falls with antiplatelet cause serious bleeding
• More polypharmacy - more interactions
• Cognitive change can affect adherence to twice-daily schedule
• More competing conditions - CAD, HF, AF, CKD all common
• Headache burden may be worse initially - some evidence of higher discontinuation in older adults

Practical adjustments in older adults

• Standard dose usually appropriate but consider gradual titration
• More attention to headache management
• PPI cover strongly considered (age is a GI bleeding risk factor)
• Blood pressure control aggressive - reduces both stroke and intracranial bleeding risk
• Fall prevention (home safety, physiotherapy, appropriate aids)
• Weekly pillbox for adherence
• Consider once-daily clopidogrel as alternative
• Assess capacity for twice-daily adherence in cognitively impaired

Frailty over age

A fit 82-year-old with well-controlled BP and no falls can benefit substantially from Aggrenox. A frail 72-year-old with recurrent falls, cognitive impairment, and polypharmacy is at high bleeding risk with limited absolute stroke reduction. Individual assessment beats chronological age.

Recognising toxicity in older adults

• 🔴 New falls - review for postural hypotension
• 🔴 New confusion - consider intracranial haemorrhage particularly after head injury
• 🔴 New anaemia - possible occult GI bleeding
• 🔴 Persistent headache after months - reassess
• 🔴 Any concerning symptom on stable therapy - consider drug-related

Deprescribing consideration

In advanced age or terminal illness, secondary stroke prevention may not add proportionate value. Deprescribing can reduce bleeding risk and simplify medication burden. Discuss as part of periodic review. Life expectancy and personal preferences guide the decision.

Sick day rules

Emergency scenarios during illness

• 🔴 New focal neurological symptoms - possible recurrent stroke
• 🔴 Severe headache different from usual dipyridamole pattern
• 🔴 Bleeding (GI, urinary, unusual bruising)
• 🔴 Head injury
• 🔴 Severe wheeze or respiratory distress
• 🔴 Chest pain

Hospital admission

• Tell admitting team about Aggrenox and stroke history
• Confirm continuation plan
• Hold before elective surgery per protocol (Section 30)
• Note the antiplatelet status if trauma or emergency surgery
• Review of concurrent new medications for interactions
• Any new bleeding needs attention

Recommended vaccines

• 🟢 Annual influenza vaccine - reduces cardiovascular and stroke events post-infection
• 🟢 Pneumococcal vaccines
• 🟢 COVID-19 vaccines
• 🟢 Shingrix (recombinant zoster) for over 50
• 🟢 Tdap booster
• 🟢 Travel vaccines as needed
• 🟢 MMR (live) - not contraindicated by Aggrenox

Injection site bleeding consideration

• Aggrenox contains aspirin - modest bleeding tendency
• Apply firm pressure to injection site for 5-10 minutes
• Use fine needle (23-25 gauge)
• Deltoid preferred site
• No need to hold Aggrenox for vaccination
• Occasional haematoma but rarely severe

Dipyridamole in pregnancy

• FDA Pregnancy Category B - animal studies show no fetal harm; limited human data
• No teratogenic effects documented in available literature
• Used in some antiphospholipid syndrome pregnancy protocols
• Used in some mechanical valve pregnancy scenarios
• The aspirin component of Aggrenox has more concerns (particularly high dose or late pregnancy)

Aspirin component in pregnancy

• 🔴 Low-dose aspirin (75-100 mg) is safe in pregnancy - widely used for preeclampsia prevention
• 🔴 Higher-dose aspirin third trimester - premature ductus arteriosus closure risk
• 🔴 Peri-delivery bleeding risk considered
• 🔴 Aggrenox aspirin component (50 mg total daily) is low dose
• 🔴 Discuss with obstetrics if pregnancy planned or occurs

Pregnancy planning

• Discuss with neurologist or GP
• Review underlying stroke aetiology - some causes need specific pregnancy management
• Consider whether antiplatelet still indicated (some post-stroke clients can transition after years)
• Some clients continue Aggrenox; others switch to aspirin monotherapy
• Multidisciplinary care with obstetrics

Fertility considerations

Dipyridamole has no known direct fertility effects. The underlying condition (prior stroke, mechanical valve) matters more than the medication for pregnancy planning.

Dipyridamole and breastfeeding

• Low levels in breast milk
• No adverse infant effects documented in available literature
• LactMed database considers it acceptable with monitoring
• Aspirin component - considered acceptable at low doses in breastfeeding
• Watch infant for unusual bruising, irritability (unlikely at these doses)

Practical approach

• Discuss with treating team and paediatrician
• If Aggrenox essential and breastfeeding preferred, considered generally acceptable
• If Aggrenox essential and safety concern, formula feeding is alternative
• If stroke prevention can be simplified to aspirin monotherapy, some clients switch during breastfeeding

General principles

• Balance surgical bleeding risk against stroke recurrence risk during hold
• Aggrenox platelet effect persists for platelet lifespan (roughly 7-10 days) because aspirin permanently acetylates COX-1
• Dipyridamole reversible effect is shorter (48 hours)
• Individual procedure bleeding risk varies substantially
• Bridging not usually needed for antiplatelet (unlike anticoagulant)

Procedure-specific approach

Restart timing

• Restart as soon as haemostasis secure - typically 24-72 hours post-op
• Do not delay unnecessarily - stroke risk during hold
• Some centres use aspirin monotherapy during hold period as bridge
• Communicate restart plan clearly at discharge

The main alternatives

• Clopidogrel 75 mg daily - once-daily P2Y12 inhibitor; simpler regimen; similar efficacy to Aggrenox in PRoFESS
• Aspirin 75-100 mg daily - simplest; cheapest; still effective
• Ticagrelor (with aspirin) - some evidence in specific stroke settings (THALES)
• Cilostazol - alternative particularly in Asian populations

When to consider switching from Aggrenox

• Persistent severe headache beyond 4 weeks despite paracetamol
• GI intolerance from aspirin component
• Bleeding complications
• Twice-daily dosing adherence problem
• New indication for anticoagulation (AF, VTE)
• New coronary intervention needing different antiplatelet
• Aspirin sensitivity or true aspirin allergy
• Client preference

Practical switch approach

1. Discuss with treating team
2. Straight switch usually appropriate (no cross-titration)
3. Stop Aggrenox one day, start new antiplatelet next day
4. Follow-up review at 4-8 weeks to assess new tolerance
5. Continued vigilance for bleeding or ischaemic events

When Aggrenox is preferable to alternatives

• Stable client tolerating well
• Cost advantage in specific markets
• Access to clopidogrel limited
• Client preference for combination
• Specific individual factors favouring the combined mechanism

Absolute contraindications

• Known hypersensitivity to dipyridamole (or aspirin for Aggrenox)
• Active peptic ulcer disease - aspirin component
• Active clinically significant bleeding
• Acute MI or unstable angina - risk of coronary steal
• Severe symptomatic asthma or reactive airways - bronchospasm risk
• Aspirin-exacerbated respiratory disease (Samter's triad) - Aggrenox contains aspirin
• Children under 16 with viral illness - Reye syndrome risk from aspirin
• Severe uncontrolled hypertension

Relative contraindications - use with caution

• Stable coronary artery disease with anginal symptoms
• Recent MI (over 4-6 weeks, stable)
• Prior GI bleeding
• Uncontrolled hypertension
• Severe renal impairment (aspirin component concerns)
• Severe hepatic impairment
• Concurrent anticoagulation
• History of falls with prior significant injury
• Aortic stenosis (fixed obstruction)
• Migraine (may worsen initially)
• Well-controlled asthma or COPD (monitor)

Reasons to stop permanently

• Major bleeding
• Severe intolerance despite management
• New indication for anticoagulation (usually replaces antiplatelet)
• New coronary intervention needing different antiplatelet regimen
• Development of severe asthma or bronchospasm on therapy
• Development of aspirin sensitivity
• Advanced age with high bleeding risk exceeding benefit
• Palliative goals in advanced disease

Discuss any stopping with treating team

Silent discontinuation of secondary stroke prevention raises recurrence risk. Almost every reason to stop has an alternative - switch antiplatelet, adjust dose, add PPI cover. Discuss before stopping.

Storage

• Room temperature under 25 C in original packaging
• Protect from light and moisture
• Not in bathroom
• Not in hot car
• Out of reach of children (aspirin component particularly)
• Do not use past expiry
• Return unused to pharmacy

Travel

• Pack in hand luggage - not checked
• Take 30 percent extra supply
• Original packaging with pharmacy label for customs
• Travel letter from treating team for overseas trips
• Time zones - shift doses gradually if crossing over 4 hours
• Long-haul flights - walk regularly, hydration, compression stockings for VTE prevention
• Medical alert bracelet noting antiplatelet therapy
• Travel insurance - declare condition and medication
• Head injury or bleeding while abroad - low threshold for medical review

Yearly review checklist

• Confirm indication and continuation still appropriate
• Blood pressure - target under 130/80 or as advised
• Lipid profile - statin optimisation
• Blood count and renal function
• HbA1c if diabetic
• Symptom review - headache, dizziness, bleeding, GI, respiratory
• Medication reconciliation - flag interactions
• Fall risk assessment
• Screening for AF if not previously detected
• Carotid imaging follow-up if applicable
• Alcohol intake conversation
• Weight and lifestyle
• Vaccination status
• Deprescribing discussion in appropriate contexts
• Consider once-daily alternative if adherence difficult

A closing thought

Persantine has an unusual history. Developed originally as a coronary vasodilator in 1961, it disappointed for that use over decades. Rather than being discarded, its antiplatelet properties were characterised and applied in secondary stroke prevention - where the ESPS-2 and ESPRIT trials established its combined benefit with aspirin. It sits alongside clopidogrel and aspirin monotherapy as a reasonable first-line antiplatelet regimen for non-cardioembolic stroke prevention. The characteristic headache and twice-daily dosing keep it from being the simplest choice for many, but for those who tolerate it, it delivers meaningful long-term stroke reduction at very modest cost. Dipyridamole's adenosine mechanism also gave nuclear cardiology one of its most useful pharmacologic stressors - a second life for a drug whose first career underwhelmed. Taken faithfully twice daily with attention to headache management in the early weeks, dipyridamole plus aspirin remains a valid tool in the stroke prevention armamentarium.